ME02887B - 2- (2,4,5-SUBSTITUTED-ANILIN) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS FOR THE TREATMENT OF CANCER - Google Patents

2- (2,4,5-SUBSTITUTED-ANILIN) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS FOR THE TREATMENT OF CANCER

Info

Publication number
ME02887B
ME02887B MEP-2017-290A MEP2017290A ME02887B ME 02887 B ME02887 B ME 02887B ME P2017290 A MEP2017290 A ME P2017290A ME 02887 B ME02887 B ME 02887B
Authority
ME
Montenegro
Prior art keywords
compound
pharmaceutically acceptable
cancer
acceptable salt
amino
Prior art date
Application number
MEP-2017-290A
Other languages
German (de)
French (fr)
Unknown language (me)
Inventor
Vasantha Krishna Kadambar
Sam Butterworth
Maurice Raymond Verschoyle Finlay
Richard Andrew Ward
Chandrasekhara Reddy Chintakuntla
Andiappan Murugan
Claudio Edmundo Chuaqui
Heather Marie Redfearn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02887(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ME02887B publication Critical patent/ME02887B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Luminescent Compositions (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Claims (12)

1. Jedinjenje naznačeno time što je izabrano od N-(2-[2-dimetilaminoetil-metilamino]-5-{[4-(1H-indol-3-il)pirimidin-2-il]amino}-4-metoksifenil)-prop-2-enamida: i N-(4-metoksi-5-{[4-(1-metilindol-3-il)pirimidin-2-il]amino}-2-[metil-(2-metilaminoetil)amino]fenil)prop-2-enamida: ili njihova farmaceutski prihvatljiva so.1. A compound selected from N-(2-[2-dimethylaminoethyl-methylamino]-5-{[4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-4-methoxyphenyl) -prop-2-enamide: and N-(4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}-2-[methyl-(2-methylaminoethyl)amino ]phenyl)prop-2-enamide: or a pharmaceutically acceptable salt thereof. 2. Jedinjenje prema zahtevu 1 naznačeno time što je N-(2-[2-dimetilaminoetil-metilamino]-5-{[4-(1H-indol-3-il)pirimidin-2-il]amino}-4-metoksifenil)-prop-2-enamid2. The compound according to claim 1 characterized in that N-(2-[2-dimethylaminoethyl-methylamino]-5-{[4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-4-methoxyphenyl )-prop-2-enamide 3. Jedinjenje kako je zatraženo u zahtevu 1, naznačeno time što je N-(4-metoksi-5-{[4-(1-metilindol-3-il)pirimidin-2-il]amino}}-2-[metil-(2-metilaminoetil)amino]fenil)prop-2-enamid.3. A compound as claimed in claim 1, characterized in that N-(4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}}-2-[methyl -(2-methylaminoethyl)amino]phenyl)prop-2-enamide. 4. Farmaceutska kompozicija, naznačena time, što sadrži jedinjenje ili neku njegovu farmaceutski prihvatljivu so kao šta se zahteva u bilo kojem od zahteva od 1 do 3 zajedno sa nekim farmaceutski prihvatljivim razređivačem ili nosiocem.4. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 3 together with a pharmaceutically acceptable diluent or carrier. 5. Jedinjenje ili neka njegova farmaceutski prihvatljiva so kao šta se zahteva u bilo kojem od zahteva od 1 do 3, naznačeno time, što se upotrebljava kao lek.5. A compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 3 for use as a medicine. 6. Jedinjenje ili neka njegova farmaceutski prihvatljiva so kao šta se zahteva u bilo kojem od zahteva od 1 do 3, naznačeno time, što se koristi u tretmanu raka.6. A compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 3 for use in the treatment of cancer. 7. Jedinjenje ili neka njegova farmaceutski prihvatljiva so prema zahtevu 6, naznačeno time, što karcinom je nesitnoćelijski karcinom pluća.7. The compound or a pharmaceutically acceptable salt thereof according to claim 6, characterized in that the cancer is non-small cell lung cancer. 8. Jedinjenje ili neka njegova farmaceutski prihvatljiva so kao šta se zahteva u bilo kojem od zahteva od 1 do 3, naznačeno time, što se upotrebljava u tretmanu bolesti koje su posredovane mutantom L858R EGFR i/ili mutantom T790M EGFR i/ili mutantom koji aktiviše deleciju Egzona 19.8. A compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 3, characterized in that it is used in the treatment of diseases mediated by the L858R EGFR mutant and/or the T790M EGFR mutant and/or the activating mutant Exon 19 deletion. 9. Farmaceutski proizvod koji sadrži jedinjenje ili neku njegovu farmaceutski prihvatljiva so, kao šta se zahteva u bilo kojem od zahteva od 1 do 3, i dodatnu anti-tumorsku supstanciju, naznačen time, što se koristi za objedinjeni tretman raka.9. A pharmaceutical product containing a compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, and an additional anti-tumor substance, indicated to be used for the combined treatment of cancer. 10. Farmaceutski produkt kao šta se zahteva u zahtevu 9, naznačen time, što pomenuti rak je nesitnoćelijski karcinom pluća.10. A pharmaceutical product as claimed in claim 9, characterized in that said cancer is non-small cell lung cancer. 11. Jedinjenje ili neka njegova farmaceutski prihvatljiva so, kao šta se zahteva u bilo kojem od zahteva od 1 do 3, i neka dodatna anti-tumorska supstancija, naznačeno time, što se upotrebljava u objedinjenom tretmanu raka.11. A compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 3 and an additional anti-tumor substance for use in the combined treatment of cancer. 12. Jedinjenje ili neka njegova farmaceutski prihvatljiva so, kao šta se zahteva u bilo kojem od zahteva od 1 do 3, i neka dodatna anti-tumorska supstancija, naznačeno time, što se upotrebljava u objedinjenom tretmanu nesitnoćelijskog karcinoma pluća.12. A compound or a pharmaceutically acceptable salt thereof, as claimed in any of claims 1 to 3, and an additional anti-tumor substance, for use in the combined treatment of non-small cell lung cancer.
MEP-2017-290A 2011-07-27 2012-07-25 2- (2,4,5-SUBSTITUTED-ANILIN) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS FOR THE TREATMENT OF CANCER ME02887B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512061P 2011-07-27 2011-07-27
US201261591363P 2012-01-27 2012-01-27
EP15192658.1A EP3009431B1 (en) 2011-07-27 2012-07-25 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer

Publications (1)

Publication Number Publication Date
ME02887B true ME02887B (en) 2018-04-20

Family

ID=46875901

Family Applications (3)

Application Number Title Priority Date Filing Date
MEP-2016-34A ME02382B (en) 2011-07-27 2012-07-25 2- (2,4,5-SUBSTITUTED) ANILINE PYRIMIDINE DERIVATIVES AS EGFR MODULATORS FOR THE TREATMENT OF CANCER
MEP-2020-87A ME03785B (en) 2011-07-27 2012-07-25 2- (2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATMENT OF CANCER
MEP-2017-290A ME02887B (en) 2011-07-27 2012-07-25 2- (2,4,5-SUBSTITUTED-ANILIN) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS FOR THE TREATMENT OF CANCER

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MEP-2016-34A ME02382B (en) 2011-07-27 2012-07-25 2- (2,4,5-SUBSTITUTED) ANILINE PYRIMIDINE DERIVATIVES AS EGFR MODULATORS FOR THE TREATMENT OF CANCER
MEP-2020-87A ME03785B (en) 2011-07-27 2012-07-25 2- (2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATMENT OF CANCER

Country Status (38)

Country Link
US (8) US8946235B2 (en)
EP (7) EP3686194B1 (en)
JP (3) JP5427321B2 (en)
KR (3) KR101410902B1 (en)
CN (7) CN103702990B (en)
AR (1) AR087336A1 (en)
AU (1) AU2012288626C1 (en)
BR (4) BR112014001768B1 (en)
CA (5) CA2882018C (en)
CL (1) CL2013003281A1 (en)
CO (1) CO6811863A2 (en)
CR (1) CR20130629A (en)
CY (4) CY1117431T1 (en)
DK (5) DK3009431T3 (en)
DO (1) DOP2013000263A (en)
EA (3) EA024421B1 (en)
EC (1) ECSP13013033A (en)
ES (5) ES2654177T3 (en)
GT (1) GT201300288A (en)
HR (4) HRP20160135T1 (en)
HU (4) HUE026429T2 (en)
IL (6) IL229199A (en)
LT (3) LT3009431T (en)
ME (3) ME02382B (en)
MX (3) MX2014000528A (en)
MY (2) MY194532A (en)
NI (1) NI201300134A (en)
PE (1) PE20141700A1 (en)
PH (2) PH12013502312A1 (en)
PL (5) PL3333161T3 (en)
PT (4) PT3686193T (en)
RS (4) RS60190B1 (en)
SG (5) SG194783A1 (en)
SI (4) SI3333161T1 (en)
SM (3) SMT202100652T1 (en)
TW (3) TWI583386B (en)
UY (1) UY34219A (en)
WO (1) WO2013014448A1 (en)

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2300013T5 (en) 2008-05-21 2025-04-28 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
KR101769999B1 (en) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Nmda receptor modulators and uses thereof
CN102498115B (en) 2009-08-20 2016-12-07 卡鲁斯治疗有限公司 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
ES2654177T3 (en) 2011-07-27 2018-02-12 Astrazeneca Ab Derivatives of 2- (2,4,5-substituted anilino) pyrimidine as EGFR modulators useful in treating cancer
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
JP6469567B2 (en) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Compound for inhibiting cell proliferation of EGFR-activated cancer
SI2951183T1 (en) 2013-01-29 2019-07-31 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120784A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP2968291B1 (en) 2013-03-15 2025-04-16 Pharmacosmos Holding A/S Hspc-sparing treatments for rb-positive abnormal cellular proliferation
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP3052494B1 (en) * 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazole compounds as inhibitors of t790m containing egfr mutants
CN104292142B (en) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 A kind of de- aryl method of N- aryl-heterocyclic butane
US20170050936A1 (en) 2013-08-23 2017-02-23 Neupharma, Inc. Certain chemical entities, compositions, and methods
HUE044683T2 (en) * 2013-10-21 2019-11-28 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
CN104761544B (en) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 The selective depressant of the important mutant of clinic of EGFR tyrosine kinase
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
CN104860941B (en) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4-disubstituted phenyl-1,5-diamine derivatives and use thereof, and pharmaceutical composition and medicinal composition prepared from 2,4-disubstituted phenyl-1,5-diamine derivative
AU2015242407B2 (en) * 2014-04-04 2017-11-09 Astrazeneca Ab Combination of EGFR inhibitor and MEK inhibitor for use in the treatment of NRAS mutated cancer
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US20170166598A1 (en) * 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN111892579B (en) * 2014-06-12 2023-07-25 上海艾力斯医药科技股份有限公司 Kinase inhibitors
BR112016029662B1 (en) * 2014-06-19 2023-10-24 Takeda Pharmaceutical Company Limited COMPOUND OF FORMULA Bf OR A PHARMACEUTICALLY ACCEPTABLE FORM THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE
CN105254615B (en) * 2014-07-11 2017-02-22 杭州华东医药集团新药研究院有限公司 Phenylaminopyrimidine derivatives and their use in preparation of drugs for resisting cancers
CN105315285B (en) * 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4 2 substitution 7H pyrrolo-es [2,3 d] pyrimidine derivatives, its preparation method and purposes pharmaceutically
CN105315259B (en) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 Pyridine amine pyrimidine derivates, its preparation method and application
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
CN104140418B (en) * 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2,4,5-substituted aniline) pyrimidine derivatives and application thereof
CN113121575A (en) * 2014-08-25 2021-07-16 四川海思科制药有限公司 (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof
CN104356040A (en) * 2014-09-17 2015-02-18 爱斯特（成都）生物制药有限公司 Preparation method of 1-benzhydryl-3-hydroxylazetidine hydrochloride
CN105461695B (en) * 2014-09-29 2018-03-27 齐鲁制药有限公司 Pyrimidine or pyrrolotriazine derivatives and its production and use
CN105524068B (en) 2014-09-30 2017-11-24 上海海雁医药科技有限公司 Azabicyclic derivatives, its preparation method and purposes pharmaceutically
CN105237515B (en) * 2014-10-10 2018-06-05 益方生物科技（上海）有限公司 Deuterated pyrimidines, its preparation method, pharmaceutical composition and purposes
SI3205650T1 (en) * 2014-10-11 2021-10-29 Shanghai Hansoh Biomedical Co Ltd Egfr inhibitor, and preparation and application thereof
HRP20250213T1 (en) * 2014-10-13 2025-04-25 Yuhan Corporation COMPOUNDS AND PREPARATIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITY
CN105085489B (en) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 Pyrimidine or pyridine compound, its preparation method and medical use
JP6769962B2 (en) * 2014-12-03 2020-10-14 オークランド ユニサービシーズ リミティド Kinase inhibitor prodrugs for cancer treatment
SG11201704685TA (en) * 2014-12-11 2017-07-28 Beta Pharma Inc Substituted 2-anilinopyrimidine derivatives as egfr modulators
WO2016105525A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
CN104961731A (en) * 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 Phosphate of epidermal growth factor receptor inhibitor, and crystal form and preparation method thereof
CN104788427B (en) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3 (2 pyrimdinyl-amino) phenylacryloyl amine compounds and its application
CN107613769A (en) 2015-02-17 2018-01-19 润新生物公司 Certain chemical entities, compositions and methods
TWI687420B (en) * 2015-04-29 2020-03-11 大陸商南京聖和藥業股份有限公司 Fused-ring or tricyclic aryl pyridine compuond used as kinase inhibitor
JP6457697B2 (en) 2015-04-29 2019-01-23 カントン チョンション ファーマシューティカル カンパニー，リミティド Fused cyclic or tricyclic arylpyrimidine compounds as kinase inhibitors
CN104817541B (en) * 2015-05-11 2017-06-16 苏州东南药业股份有限公司 A kind of synthetic method of antineoplastic
WO2016183278A1 (en) * 2015-05-13 2016-11-17 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
EP3294299A1 (en) 2015-05-15 2018-03-21 Novartis AG Methods for treating egfr mutant cancers
CN104910049B (en) 2015-06-16 2016-06-29 苏州明锐医药科技有限公司 AZD9291 intermediate and preparation method thereof
KR102666414B1 (en) 2015-07-16 2024-05-17 치아타이 티안큉 파마수티컬 그룹 주식회사 Aniline pyrimidine derivatives and their uses
WO2017015363A1 (en) * 2015-07-20 2017-01-26 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
WO2017016463A1 (en) * 2015-07-24 2017-02-02 上海海雁医药科技有限公司 Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
CN105001208A (en) * 2015-08-06 2015-10-28 南京雷科星生物技术有限公司 EGFR inhibitor and preparing method and application thereof
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
CN106117185B (en) 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4 2 nitrogen-containing group substituted uracil compounds and its preparation method and application
KR102051609B1 (en) * 2015-08-31 2019-12-03 우시 상량 바이오테크놀로지 씨오., 엘티디. 2-arylaminopyridine, pyrimidine or triazine derivatives and methods for their preparation and use
CN110483485A (en) * 2015-09-02 2019-11-22 益方生物科技（上海）有限公司 Pyrimidines, preparation method and medical usage
RU2606949C9 (en) * 2015-11-19 2018-03-14 ЗАО "Р-Фарм" Substituted n-{3-[4-(1-methyl-1h-indol-3-yl)pyrimidin-2-ylamino]-4-methoxyphenyl}-amides as modulators of egfr, applicable for treating cancer
RU2603960C1 (en) * 2015-11-19 2016-12-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Dichloroacetate of n1,n2-disubstituted n4-[4-(1-methyl-1h-indole-3-yl)-pyrimidine-2-yl]-5-methoxybenzene-1,2,4-triamine as egfr modulator for treating cancer
CN106749267B (en) * 2015-11-23 2020-08-21 南京圣和药业股份有限公司 Novel epidermal growth factor receptor inhibitors and uses thereof
CN106810553B (en) * 2015-11-30 2020-03-17 江苏正大丰海制药有限公司 3- (4, 5-substituted aminopyrimidine) phenyl derivative and application thereof
US10829495B2 (en) 2015-12-03 2020-11-10 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
EP3383877B1 (en) * 2015-12-03 2021-09-15 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Heterocycle compounds and uses thereof
CN105601620A (en) * 2015-12-25 2016-05-25 北京康立生医药技术开发有限公司 Method for preparing mereletinib mesylate
CN106928150B (en) 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 Acrylamide aniline derivative and pharmaceutical application thereof
JP2019501222A (en) 2016-01-07 2019-01-17 シーエス ファーマテック リミテッド Selective inhibitors of clinically important variants of EGFR tyrosine kinase
CN105646454B (en) * 2016-01-19 2018-05-08 浙江大学 The 2- aryl amine pyridine derivatives of the fragment containing hydroxamic acid and preparation and application
CN108610331A (en) * 2016-01-22 2018-10-02 焦玉奇 2- (2,4,5- substituted anilines) pyrimidine derivatives
CN106995437A (en) * 2016-01-22 2017-08-01 齐鲁制药有限公司 Substituted indole or indazole pyrimidine derivatives and its production and use
TWI745345B (en) 2016-02-01 2021-11-11 瑞典商阿斯特捷利康公司 Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and “azd9291 aniline” or a salt thereof
CN107043368B (en) * 2016-02-05 2020-07-31 齐鲁制药有限公司 Crystals of arylamine pyrimidine compounds and salts thereof
CN107043369A (en) * 2016-02-06 2017-08-15 焦玉奇 2 (2,4,5 substituted aniline) pyrimidine derivatives
CN107098887B (en) * 2016-02-22 2019-08-09 复旦大学 Pyrimidines
CN105777716B (en) * 2016-02-25 2018-04-10 清华大学 A kind of EGFR inhibitor for targeted therapy of cancer and preparation method and application
CN105646467B (en) * 2016-02-25 2018-07-20 黄燕鸽 A kind of anticancer compound Aomei replaces Buddhist nun and its synthetic method
CN105585557B (en) * 2016-02-25 2018-06-22 清华大学 EGFR inhibitor for targeted therapy of cancer and preparation method and application
CN107163027B (en) 2016-03-07 2019-11-05 上海艾力斯医药科技有限公司 Crystalline form of pyridylaminopyrimidine derivative mesylate and its preparation and application
CN107163026B (en) * 2016-03-07 2019-07-02 上海艾力斯医药科技有限公司 The salt and its preparation method and application of pyridine amine pyrimidine derivates
CN107188888A (en) * 2016-03-15 2017-09-22 罗欣生物科技（上海）有限公司 A kind of methanesulfonic acid for preparing steps the auspicious method for Buddhist nun
JP7007287B2 (en) * 2016-03-22 2022-01-24 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド Polycrystalline form of EGFR inhibitor free base or acid salt, its production method, and application
KR20190006991A (en) * 2016-05-11 2019-01-21 베타 파마, 인크. 2-anilinopyrimidine derivatives as therapeutics for the treatment of brain cancer
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3464275B1 (en) 2016-05-26 2024-05-08 Recurium IP Holdings, LLC Egfr inhibitor compounds
AU2017285448B2 (en) * 2016-06-17 2021-02-04 Beta Pharma, Inc. Pharmaceutical salts of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
CN107522690B (en) * 2016-06-20 2022-08-05 海南先声药业有限公司 Preparation method of Osimetinib
CN107540661A (en) * 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 Crystallization as the Aniline pyrimidine compound of EGFR inhibitor
CN107663207B (en) * 2016-07-27 2021-07-30 南京圣和药业股份有限公司 Mesylate crystal of EGFR kinase inhibitor and preparation method thereof
CN107663208B (en) * 2016-07-27 2021-10-15 南京圣和药业股份有限公司 Medicinal salt of novel EGFR kinase inhibitor and preparation method and application thereof
WO2018026763A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX383650B (en) 2016-08-01 2025-03-14 Aptinyx Inc NMDA SPIRO-LACTAM RECEPTOR MODULATORS AND THEIR USE.
JP7032378B2 (en) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド Spiro-lactam NMDA receptor modifiers and their use
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN106366072B (en) * 2016-08-19 2018-12-07 上海工程技术大学 A kind of preparation method of AZD9291
CN106366022B (en) * 2016-08-19 2018-03-13 上海工程技术大学 It is a kind of to be used to prepare AZD9291 intermediate and its preparation method and application
CN106397407B (en) * 2016-08-31 2018-09-04 浙江科聚化工有限公司 The preparation method of antitumor drug AZD9291 derivatives
CN106432231B (en) * 2016-09-09 2018-06-12 无锡佰翱得生物科学有限公司 The pharmaceutical salts and its crystal form and preparation method of AZD9291
US10654851B2 (en) * 2016-09-19 2020-05-19 Nanjing Chuangte Pharmaceutical Technology Co., Ltd. Deuterated 3-(4,5-substituted aminopyrimidine)phenyl derivatives and use thereof
CN107955019B (en) * 2016-10-17 2021-09-14 广东众生药业股份有限公司 Salt form and crystal form of EGFR inhibitor and preparation method thereof
WO2018073839A1 (en) 2016-10-18 2018-04-26 Mylan Laboratories Limited Amorphous osimertinib mesylate, processes for its preparation and solid amorphous dispersions thereof
EP3528798A4 (en) * 2016-10-19 2020-10-21 United States Government as Represented by The Department of Veterans Affairs COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
CN106496196B (en) * 2016-10-20 2019-07-02 南京雷科星生物技术有限公司 A kind of quinazoline, Pyridopyrimidine or double and pyrimidine derivatives egf inhibitor and preparation method thereof and purposes
CN106543060B (en) * 2016-10-31 2018-11-06 湖南欧亚药业有限公司 A kind of difficult to understand this replaces the preparation method of Buddhist nun's mesylate
CN108299419B (en) * 2017-01-11 2022-04-26 南京圣和药业股份有限公司 Novel crystal forms of novel EGFR kinase inhibitor and preparation method thereof
PL3514153T3 (en) 2017-01-26 2022-01-17 Hanmi Pharm. Co., Ltd. Pyrimidine compound and pharmaceutical use thereof
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. TREATMENT OF EGFR MEDIATED CANCER WITH LESS SIDE EFFECTS
TWI796326B (en) 2017-03-24 2023-03-21 日商第一三共股份有限公司 Medicines containing axl inhibitor and egfr tyrosine kinase inhibitor and uses thereof
CN106883216B (en) * 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 Preparation method of oxitinib
CN108503627A (en) * 2017-04-19 2018-09-07 郑州泰基鸿诺医药股份有限公司 2,4- disubstituted benzenes -1,5- diamine derivatives as EGFR inhibitor and its application
AR111469A1 (en) * 2017-04-21 2019-07-17 Yuhan Corp COME OUT OF AN AMINOPIRIDINE DERIVATIVE COMPOUND, A CRYSTAL FORM OF THE SAME, AND A PROCESS TO PREPARE THE SAME
CN106967050A (en) * 2017-05-11 2017-07-21 北京工业大学 A kind of AZD9291 preparation method
CN108929311B (en) * 2017-05-22 2020-07-28 焦玉奇 2- (2,4, 5-substituted aniline) pyrimidine derivatives
CN108558835B (en) 2017-05-24 2024-08-16 浙江同源康医药股份有限公司 A crystal form, preparation method and use of deuterated AZD9291
CN107176954B (en) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 A kind of pharmaceutical salts and its crystal form, preparation method and application of EGFR inhibitor
KR102388312B1 (en) * 2017-06-13 2022-04-19 베이징 아다메이들 바이오테크놀로지 리미티드 라이어빌리티 컴퍼니 Aminopyrimidine compound, preparation method and use thereof
TW201904577A (en) 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-Dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl Pharmaceutical formulation of amino)phenyl) acrylamide and its salts
WO2019001425A1 (en) * 2017-06-27 2019-01-03 浙江同源康医药股份有限公司 Deuterated osimertinib derivative and application thereof
CN107095873A (en) * 2017-06-28 2017-08-29 卢凯华 Anti-lung cancer targeted medicament composition with low drug resistance
CN107216313B (en) * 2017-06-29 2019-11-19 山东四环药业股份有限公司 A preparation method of antitumor drug AZD9291
WO2019010619A1 (en) * 2017-07-10 2019-01-17 焦玉奇 2-(2,4,5-substituted aniline) pyrimidine derivative
DK3658552T3 (en) 2017-07-28 2023-11-20 Yuhan Corp PROCEDURE FOR THE PREPARATION OF N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2- MORPHOLINOPHENYL)ACRYLAMIDE BY REACTION OF THE CORRESPONDING AMINE WITH A 3-HALOGEN-PROPIONYL CHLORIDE
PT3658547T (en) * 2017-07-28 2023-10-20 Yuhan Corp Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
CN107266426A (en) * 2017-08-15 2017-10-20 南通因诺威医药科技有限公司 2-Aminoalkylpyrimidines and their preparation and use
JP7135068B2 (en) 2017-08-21 2022-09-12 イーライ リリー アンド カンパニー Combination of EGFR inhibitor and anti-human VEGFR-2 antibody
CN109485638B (en) * 2017-09-12 2020-07-17 新发药业有限公司 Preparation method of oxitinib intermediate
CN107915725B (en) * 2017-10-20 2023-06-27 复旦大学 Medicinal salt of AZD9291 and preparation method thereof
SG11202004384YA (en) * 2017-11-17 2020-06-29 Univ Illinois Cancer therapy by degrading dual mek signaling
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
WO2019152696A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN112204031B (en) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 Spiro-lactam NMDA receptor modulators and their uses
EP3749310B1 (en) * 2018-02-08 2025-11-26 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2019219304A1 (en) * 2018-02-12 2020-09-24 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
WO2019164945A1 (en) * 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Pharmaceutical combinations of egfr inhibitors and methods of use thereof
WO2019164949A1 (en) * 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Pharmaceutical combinations of egfr inhibitors and methods of use thereof
CN108250187B (en) * 2018-03-01 2021-01-05 中国科学院上海药物研究所 Indole-1-carbonate compound, its preparation method and application
CN108191861B (en) * 2018-03-01 2020-10-02 天津大学 N-[5-(Pyrimidine-2-amino)-2,4-disubstituted phenyl]-trans-2,4-pentadienamide
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
CN108218839A (en) * 2018-03-20 2018-06-29 上药康丽（常州）药业有限公司 A kind of preparation method of antitumor drug AZD9291
CN109666024A (en) * 2018-03-20 2019-04-23 兰州大学 2- oxygen pyrimidines and its preparation method and application
CN108484579A (en) * 2018-03-28 2018-09-04 黑龙江鑫创生物科技开发有限公司 A kind of micro passage reaction synthesis uncommon method for Buddhist nun's intermediate difficult to understand
CN108530450B (en) * 2018-05-03 2021-03-30 赖建智 Compound with EGFR (epidermal growth factor receptor) inhibitory activity, preparation method and application of compound in disease treatment
WO2019222093A1 (en) 2018-05-14 2019-11-21 Ariad Pharmaceuticals, Inc. Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
US11639344B2 (en) 2018-05-15 2023-05-02 InventisBio Co., Ltd. EGFR inhibitors
CN110606842B (en) * 2018-06-15 2021-06-01 上海艾力斯医药科技股份有限公司 Process for producing pyridylamino pyrimidine derivative and intermediate thereof
CN110698461B (en) * 2018-07-09 2024-04-05 上海翰森生物医药科技有限公司 Preparation method of third-generation EGFR inhibitor
KR101954370B1 (en) 2018-07-25 2019-03-05 한미약품 주식회사 Pyrimidine compounds and pharmaceutical composition for preventing or treating cancers comprising the same
WO2020072774A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
CN109134435B (en) * 2018-10-29 2023-01-03 湖南大学 Synthesis method of AZD9291
CN111233774B (en) * 2018-11-28 2023-04-14 鲁南制药集团股份有限公司 Amino pyrimidine compound
CN113195000A (en) 2018-12-21 2021-07-30 第一三共株式会社 Combination of antibody-drug conjugates and kinase inhibitors
CN113227073B (en) * 2019-01-05 2022-09-16 山东轩竹医药科技有限公司 Salts of selective inhibitors of EGFR tyrosine kinase and crystalline forms thereof
CN111410651B (en) * 2019-01-05 2021-06-04 山东轩竹医药科技有限公司 Salts of tyrosine kinase inhibitors and crystalline forms thereof
BR112021016522A2 (en) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
CN113773304B (en) * 2019-02-25 2023-03-10 江苏豪森药业集团有限公司 Preparation method of anti-drug-resistance anti-tumor EGFR inhibitor
CN111606889B (en) * 2019-02-25 2023-03-07 上海翰森生物医药科技有限公司 Preparation method of 4-(1-cyclopropyl-1H-indol-3-yl)-N-phenylpyrimidin-2-amine derivative
CN109928956B (en) * 2019-02-27 2020-10-13 杭州偶联医药科技有限公司 Compound for targeted ubiquitination degradation of EGFR protein, and pharmaceutical composition and application thereof
WO2020192302A1 (en) * 2019-03-27 2020-10-01 广州必贝特医药技术有限公司 Pyrimidine-containing tri-substituted imidazole compound and application thereof
CN111747950B (en) 2019-03-29 2024-01-23 深圳福沃药业有限公司 Pyrimidine derivatives for the treatment of cancer
MX2021011810A (en) 2019-03-29 2021-10-26 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer.
WO2020206603A1 (en) * 2019-04-09 2020-10-15 河南真实生物科技有限公司 2-(2,4,5-substituted phenylamino)pyrimidine derivative and crystal form b thereof
CN109942550A (en) * 2019-04-15 2019-06-28 广州医科大学附属第一医院（广州呼吸中心） 11EGFR positive electron tracer of C flag and its preparation method and application
WO2020222188A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
US20220296595A1 (en) 2019-05-05 2022-09-22 Qilu Regor Therapeutics Inc. Cdk inhibitors
US20220340547A1 (en) * 2019-05-22 2022-10-27 Shanghi Hansoh Biosoh Biomedical Co., Ltd. Indole derivative-containing inhibitor, preparation method therefor and application thereof
MX2021015724A (en) 2019-06-27 2022-05-16 Hanmi Pharm Ind Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA, WHICH CONTAINS FLT3 INHIBITORS AND CHEMOTHERAPEUTIC AGENTS.
CN110283162B (en) * 2019-07-09 2022-04-05 辽宁大学 A kind of epidermal growth factor receptor inhibitor and its application
CN110483486B (en) * 2019-09-17 2024-01-26 鲁南制药集团股份有限公司 Crystal form of oxtinib ketorolac and preparation method thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021111462A1 (en) * 2019-12-02 2021-06-10 Natco Pharma Limited An improved process for the preparation of osimertinib mesylate
EP4076667A1 (en) 2019-12-20 2022-10-26 Erasca, Inc. Tricyclic pyridones and pyrimidones
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
IL272441B (en) * 2020-02-03 2021-08-31 Ottek Ltd System and method for endoscope propulsion
CN113372332B (en) * 2020-03-10 2023-09-12 鲁南制药集团股份有限公司 Novel crystal form of octreotide
CN113372331B (en) * 2020-03-10 2023-09-12 鲁南制药集团股份有限公司 Novel crystal form of Orientinib monohydrate
CN111303123B (en) * 2020-03-31 2021-08-31 南京雷正医药科技有限公司 2-(2,4,5-Substituted anilino)pyrimidine compound and its application
CN111285852A (en) * 2020-04-02 2020-06-16 广州博济医药生物技术股份有限公司 Crystal form of deuterated oxitinib medicinal salt and preparation method thereof
CN111303124A (en) * 2020-04-08 2020-06-19 北京赛思源生物医药技术有限公司 Novel crystal of oxitinib mesylate
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN113801101A (en) * 2020-06-15 2021-12-17 鲁南制药集团股份有限公司 AZD 9291-2-ketoglutarate and preparation method thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN113929663B (en) * 2020-06-29 2025-06-17 鲁南制药集团股份有限公司 AZD9291-2-indolecarboxylate and its preparation method
CN113929664A (en) * 2020-07-13 2022-01-14 鲁南制药集团股份有限公司 AZD9291-3, 5-pyridine dicarboxylic acid salt and preparation method thereof
CN113968845A (en) * 2020-07-24 2022-01-25 鲁南制药集团股份有限公司 AZD 9291-gallate and preparation method thereof
US20230321098A1 (en) 2020-08-25 2023-10-12 Loxo Oncology, Inc. Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers
IL301524A (en) 2020-09-23 2023-05-01 Erasca Inc Pyridones and tricyclic pyrimidones
CN112430231B (en) * 2020-11-06 2022-09-30 德州德药制药有限公司 Industrial preparation method of AZD9291
CN112358468B (en) * 2020-11-10 2022-03-22 德州德药制药有限公司 Industrial synthesis method of AZD9291
TW202222795A (en) * 2020-11-19 2022-06-16 大陸商上海翰森生物醫藥科技有限公司 The salt, crystal form and preparation method of an indole-containing derivative
US11780824B2 (en) 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
TW202317126A (en) 2021-06-15 2023-05-01 美商建南德克公司 Egfr inhibitor and perk activator in combination therapy
CN113387935B (en) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 Compound for inhibiting triple-mutation epidermal growth factor receptor tyrosine kinase and application thereof
WO2023011505A1 (en) * 2021-08-06 2023-02-09 上海和誉生物医药科技有限公司 Pyrimidine or pyridine derivative, preparation method therefor, and application thereof in pharmacy
JP2024530782A (en) * 2021-09-02 2024-08-23 シントン・ビー．ブイ． Manufacturing process for osimertinib
CN113683612B (en) * 2021-09-07 2022-06-17 山东铂源药业股份有限公司 Preparation method of palbociclib
JP7702205B2 (en) * 2021-09-15 2025-07-03 株式会社東芝 Novel amine compound, acidic gas absorbent, method for removing acidic gas, and method for removing acidic gas
CN116099006A (en) * 2021-11-10 2023-05-12 上海交通大学医学院附属新华医院 Application of osimertinib and pharmaceutically acceptable salts thereof in the preparation of medicines for acute myeloid leukemia
CN114014847B (en) * 2021-12-08 2023-11-03 滨州医学院 A kind of benzothiophene-containing pyrimidine derivative, its preparation method and its application in preparing anti-tumor drugs
CN114380806B (en) * 2022-03-24 2022-06-10 中国药科大学 2-Amino-4-indolylpyrimidine compounds and preparation method and application thereof
CA3255389A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
AR128999A1 (en) 2022-04-07 2024-07-03 Astrazeneca Ab IMPROVED PROCESS FOR THE MANUFACTURE OF OSIMERTINIB
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
CA3250910A1 (en) * 2022-05-03 2023-11-09 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. Inhibitors of tau proteins
MA71241A (en) 2022-06-27 2025-04-30 Astrazeneca Ab COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
CN115650974B (en) * 2022-08-04 2024-06-18 天津大学 N-[5-(pyrimidine-2-amino)-2,4-disubstituted phenyl]-cis-pentadienamide derivatives and applications
CN119894871A (en) * 2022-09-19 2025-04-25 南京爱德程医药科技有限公司 Pyrimidine compounds as kinase inhibitors having biological activity against EGFR mutants
CN116655601B (en) * 2023-06-05 2025-08-29 河南应用技术职业学院 A synthetic method of osimertinib
WO2025124936A1 (en) 2023-12-15 2025-06-19 Synthon B.V. A process for making osimertinib
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (en) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-ANILINOQUINAZOLINE DERIVATIVES
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (en) 1999-02-10 2010-10-15 Astrazeneca Ab Quinazoline derivatives as inhibitors of angiogenesis
CN1431999A (en) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 Indole derivatives with vascular damagine activity
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
RU2003103603A (en) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Derivatives of colchinol as inhibitors of angiogenesis
JP2004502766A (en) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド Colhinol derivatives as vascular damaging agents
US6881737B2 (en) * 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
DE10237722A1 (en) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase
ATE430747T1 (en) * 2004-12-21 2009-05-15 Smithkline Beecham Corp 2-PYRIMIDINYL-PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
DK1848414T3 (en) 2005-02-03 2011-07-25 Gen Hospital Corp Process for the treatment of gefitinib-resistant cancer
JP5249770B2 (en) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド Aminopyridines useful as kinase inhibitors
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
EP1971606B1 (en) * 2005-12-05 2013-04-24 GlaxoSmithKline LLC 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
JP2009541318A (en) 2006-06-22 2009-11-26 メルク エンド カムパニー インコーポレーテッド Tyrosine kinase inhibitor
WO2008009458A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2702674C (en) 2007-10-19 2016-05-03 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
TWI458721B (en) * 2008-06-27 2014-11-01 Celgene Avilomics Res Inc Heteroaryl compound and its use
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102405284B (en) 2008-09-05 2016-01-20 新基阿维罗米克斯研究公司 Algorithms for Designing Irreversible Inhibitors
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (en) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 Kinase suppressor and pharmaceutical application thereof
KR101705158B1 (en) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr inhibitors and methods of treating diseases
KR101256018B1 (en) * 2009-08-20 2013-04-18 한국과학기술연구원 1,3,6-Substituted indole derivatives having inhibitory activity for protein kinase
EP2478361A4 (en) 2009-09-16 2014-05-21 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
JP2013509412A (en) * 2009-11-02 2013-03-14 アボット・ラボラトリーズ Imidazopyridines as novel scaffolds in multitarget kinase inhibition
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
LT2585470T (en) 2010-06-23 2017-04-10 Hanmi Science Co., Ltd. Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
EP2704572B1 (en) * 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
ES2654177T3 (en) 2011-07-27 2018-02-12 Astrazeneca Ab Derivatives of 2- (2,4,5-substituted anilino) pyrimidine as EGFR modulators useful in treating cancer

Also Published As

Publication number Publication date
IL242284A0 (en) 2015-11-30
CN105198862B (en) 2018-01-23
EA201391491A1 (en) 2014-08-29
AU2012288626C1 (en) 2015-09-17
BR122014026150A2 (en) 2019-05-28
CA2881987A1 (en) 2013-01-31
EP4119551A1 (en) 2023-01-18
ME02382B (en) 2016-06-20
KR20140047741A (en) 2014-04-22
ECSP13013033A (en) 2014-01-31
JP2014094930A (en) 2014-05-22
IL242279A (en) 2016-07-31
LT3686194T (en) 2021-11-25
PT3009431T (en) 2017-12-26
US20190092746A1 (en) 2019-03-28
ES2914854T3 (en) 2022-06-17
IL229199A (en) 2015-11-30
JP2014139226A (en) 2014-07-31
HK1256370A1 (en) 2019-09-20
PL3333161T3 (en) 2020-08-24
HUE056365T2 (en) 2022-02-28
CN104109151A (en) 2014-10-22
CY1120072T1 (en) 2018-12-12
CA2843109A1 (en) 2013-01-31
BR122014026094A2 (en) 2019-08-20
CN104109161B (en) 2016-08-17
PH12013502312A1 (en) 2016-07-13
CL2013003281A1 (en) 2014-07-25
EA024421B1 (en) 2016-09-30
EP2736895A1 (en) 2014-06-04
HUE037645T2 (en) 2018-09-28
PL3686193T3 (en) 2022-06-13
US20210130318A1 (en) 2021-05-06
CN103702990A (en) 2014-04-02
DOP2013000263A (en) 2014-01-31
BR122014026114A2 (en) 2019-08-20
PH12015501326B1 (en) 2015-09-14
US10017493B2 (en) 2018-07-10
WO2013014448A1 (en) 2013-01-31
CY1123210T1 (en) 2021-10-29
RS56679B1 (en) 2018-03-30
BR122014026114B1 (en) 2021-01-12
DK3009431T3 (en) 2018-01-08
CN104109161A (en) 2014-10-22
ES2654177T3 (en) 2018-02-12
US20190389834A1 (en) 2019-12-26
MY194532A (en) 2022-11-30
JP5537704B2 (en) 2014-07-02
EA033733B1 (en) 2019-11-20
SG10201910986QA (en) 2020-01-30
CA2882018A1 (en) 2013-01-31
EP4086246A1 (en) 2022-11-09
US20150119379A1 (en) 2015-04-30
ES2791308T3 (en) 2020-11-03
US11524951B2 (en) 2022-12-13
PL3686194T3 (en) 2022-01-17
ES2900230T3 (en) 2022-03-16
EA201690328A1 (en) 2016-11-30
PT3686194T (en) 2021-11-11
US20240425476A1 (en) 2024-12-26
US20240182441A1 (en) 2024-06-06
US8946235B2 (en) 2015-02-03
MX377900B (en) 2025-03-10
EA201792394A2 (en) 2018-03-30
SMT201600070B (en) 2016-04-29
CA2881991C (en) 2016-10-25
BR112014001768A2 (en) 2017-02-14
KR20140062181A (en) 2014-05-22
CN103702990B (en) 2015-09-09
CN104109151B (en) 2017-04-12
DK3333161T3 (en) 2020-05-18
DK2736895T3 (en) 2016-02-29
HUE049060T2 (en) 2020-08-28
CN105198862A (en) 2015-12-30
SI3009431T1 (en) 2018-01-31
UY34219A (en) 2013-02-28
CR20130629A (en) 2014-03-12
SI3333161T1 (en) 2020-07-31
BR122014026150B1 (en) 2020-10-13
US20130053409A1 (en) 2013-02-28
EP3009431A1 (en) 2016-04-20
KR101691268B1 (en) 2016-12-29
SG194783A1 (en) 2013-12-30
CY1125405T1 (en) 2023-03-24
EP3686194A1 (en) 2020-07-29
DK3686194T3 (en) 2021-11-22
KR101422619B1 (en) 2014-07-24
AU2012288626A1 (en) 2013-05-02
EP3333161B1 (en) 2020-02-19
PH12015501326A1 (en) 2015-09-14
PE20141700A1 (en) 2014-11-20
IL242285A0 (en) 2015-11-30
BR112014001768B1 (en) 2019-02-05
TW201319057A (en) 2013-05-16
BR122014026094B1 (en) 2020-10-13
EA201792394A3 (en) 2018-07-31
AR087336A1 (en) 2014-03-19
SG10201402860QA (en) 2014-08-28
EP3009431B1 (en) 2017-10-25
CA2881991A1 (en) 2013-01-31
NZ617393A (en) 2014-11-28
MX2014000528A (en) 2014-05-01
LT3009431T (en) 2018-01-10
CA2882018C (en) 2017-04-25
PT3686193T (en) 2022-05-20
RS54653B1 (en) 2016-08-31
RS60190B1 (en) 2020-06-30
HUE026429T2 (en) 2016-05-30
IL242278A0 (en) 2015-11-30
TW201443040A (en) 2014-11-16
KR20140030089A (en) 2014-03-11
CA2881993C (en) 2017-05-09
SI3686194T1 (en) 2022-01-31
IL229199A0 (en) 2014-01-30
TWI465445B (en) 2014-12-21
IL242278A (en) 2016-12-29
CO6811863A2 (en) 2013-12-16
SI2736895T1 (en) 2016-03-31
RS62542B1 (en) 2021-12-31
JP2013544273A (en) 2013-12-12
SG10201402857QA (en) 2014-08-28
KR101410902B1 (en) 2014-06-20
CA2843109C (en) 2015-06-16
HK1192554A1 (en) 2014-08-22
SG10201910984XA (en) 2020-01-30
HRP20160135T1 (en) 2016-03-11
PT3333161T (en) 2020-05-18
SMT202100652T1 (en) 2022-01-10
SMT202000208T1 (en) 2020-05-08
CN105175396B (en) 2018-01-16
IL242284A (en) 2016-07-31
MX2020013020A (en) 2022-06-14
AU2012288626B2 (en) 2015-05-07
CN105254616B (en) 2017-10-17
PL3009431T3 (en) 2018-02-28
CN105348266A (en) 2016-02-24
GT201300288A (en) 2017-10-09
PL2736895T3 (en) 2016-05-31
CY1117431T1 (en) 2017-04-26
IL242285A (en) 2016-07-31
CN105175396A (en) 2015-12-23
IL242286A0 (en) 2015-11-30
HK1192549A1 (en) 2014-08-22
ES2564671T3 (en) 2016-03-28
EP3333161A1 (en) 2018-06-13
US10858336B2 (en) 2020-12-08
AU2012288626A8 (en) 2013-09-26
JP5977779B2 (en) 2016-08-24
LT3333161T (en) 2020-05-11
EP3686194B1 (en) 2021-09-15
US9732058B2 (en) 2017-08-15
HRP20211682T1 (en) 2022-03-04
ME03785B (en) 2021-04-20
TWI555743B (en) 2016-11-01
DK3686193T3 (en) 2022-05-30
US20180162832A1 (en) 2018-06-14
IL242279A0 (en) 2015-11-30
CN105348266B (en) 2018-04-10
CN105254616A (en) 2016-01-20
HK1221216A1 (en) 2017-05-26
JP5427321B2 (en) 2014-02-26
HRP20171957T1 (en) 2018-02-09
MY161925A (en) 2017-05-15
TW201700099A (en) 2017-01-01
IL242286A (en) 2016-07-31
EP3686193A1 (en) 2020-07-29
HRP20200624T1 (en) 2020-07-10
EP3686193B1 (en) 2022-03-02
NI201300134A (en) 2014-02-12
EA029488B1 (en) 2018-04-30
TWI583386B (en) 2017-05-21
EP2736895B1 (en) 2016-01-06
CA2881987C (en) 2017-04-25
CA2881993A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
ME02887B (en) 2- (2,4,5-SUBSTITUTED-ANILIN) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS FOR THE TREATMENT OF CANCER
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
EA201790246A1 (en) HETEROCYCLIC CARBONIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATZYCLIC
EA201370166A1 (en) CONTAINING DIRYLACETHYLENEHYDRAZIDE THYROZINKINASE INHIBITORS
EA201690752A1 (en) INHIBITORS G12C KRAS
MX382331B (en) 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3F] ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER.
EA201691242A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AZD9291
EA201691151A1 (en) CONNECTIONS FOR THE TREATMENT OF PATIENTS WITH ROS1-MUTANT CANCER CELLS
EA201690035A1 (en) NEW CYCLIC DERIVATIVES OF AZABENZIMIDAZOLE, USED AS ANTI-DIABETIC AGENTS
EA201492125A1 (en) NEW 4- (AMINO-SUBSTITUTED) -7H-PYRROLO [2,3-d] PYRIMIDINES AS LRRK2 Inhibitors
EA201400358A1 (en) SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTAN-3-CARBOXAMIDE INHIBITORS KATEPSIN C
EA201591908A1 (en) Condensed Heterocyclic Compounds As Protein Kinase Inhibitors
PE20130405A1 (en) PIRAZOL-4-IL-HETEROCICLIL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
MX387984B (en) EGFR INHIBITOR AND ITS PREPARATION AND APPLICATION.
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
EA201001683A1 (en) Derivatives of phenyl or pyridinyl substituted indazols
EA201692166A1 (en) GLETAMINASE HETEROCYCLIC INHIBITORS
EA201290980A1 (en) DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBURONIC ACID
EA201692465A1 (en) CRYSTALLINE SALTS (S) -6 - ((1-ACETYLPIPERIDIN-4-IL) AMINO) -N- (3- (3,4-DIHYDRO-ISOHINOLIN-2 (1H) -YL) -2-HYDROXYPROPIL) Pyrimidine-4-C-Cyropyridine-4-Cyropyridine-4-Cylindiol-4-IL-2).
MY159239A (en) Urea derivatives that are kinase inhibitors, and their therapeutic use
EA201400553A1 (en) 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) picoline amide
PE20090876A1 (en) NEW 6-ARIL / HETEROALKYLOXY BENZOTHIAZOLE AND BENZHIMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCEDURE, THEIR APPLICATION AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND A NEW USE MAINLY AS CMET INHIBITORS
MD20160105A2 (en) 2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
EA201300436A8 (en) JOINT CRYSTALS AND SALTS OF CCR3 INHIBITORS
NZ630099A (en) Phenicol antibacterials